07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Versartis board of directors update

Versartis Inc. , Mountain View, Calif.   Business: Endocrine/Metabolic   Appointed: Edmon Jennings as chairman, formerly president and CEO of Angiogenix Inc. , which is no longer active  ...
07:00 , May 30, 2005 |  BC Week In Review  |  Company News

Endovasc cardiovascular news

EVSC will no longer fund research by its Angiogenix subsidiary, which has terminated its license to a preclinical nicotine receptor agonist (NRA) from Stanford University (Stanford, Calif.). The NRA license agreement contained unrealistic deadlines for...
00:37 , May 26, 2005 |  BC Extra  |  Company News

Endovasc unwinding Angiogenix

Endovasc (EVSC) said it will no longer fund research by its Angiogenix subsidiary, which has terminated its license to a preclinical nicotine receptor agonist (NRA) from Stanford University. EVSC said the NRA license agreement contained...
08:00 , Feb 7, 2005 |  BC Week In Review  |  Clinical News

Acclaim: Phase II failed

In a double-blind, placebo-controlled, international Phase II trial in 204 patients, Acclaim missed the primary endpoint of significant increase in TWT compared to nitrate therapy alone. The company will use the data from this trial...
08:00 , Jan 31, 2005 |  BC Extra  |  Clinical News

Angiogenix Phase II Acclaim data

Angiogenix (Burlingame, Calif.) said its Acclaim missed the primary endpoint in an international Phase II trial to treat chronic angina. In the double-blind trial in 204 patients, the combination of isosorbide mononitrate plus L-arginine did...
08:00 , Dec 15, 2003 |  BC Week In Review  |  Clinical News

Acclaim: Phase II

Angiogenix began a double-blind, placebo-controlled, international Phase II trial in 170 patients with coronary artery disease who suffer from chronic, stable, effort-induced angina. The primary endpoint is treadmill walking time (TWT) determined from the beginning...
07:00 , Jul 7, 2003 |  BC Week In Review  |  Company News

Endovasc, Stanford University deal

The university received a $300,000 milestone from ENDV under a 2002 deal (see BioCentury, Feb. 11, 2002). ENDV's proposed filing of an IND application for a Phase III trial of Angiogenix to treat chronic myocardial...
07:00 , Jun 23, 2003 |  BC Week In Review  |  Company News

Angiogenix management update

Angiogenix Inc. , Burlingame, Calif.   Business: Cardiovascular   Hired: Edmun Jennings as CEO and president, formerly COO at Pain Therapeutics Inc.  ...
07:00 , May 26, 2003 |  BC Week In Review  |  Company News

Endovasc, MIV Therapeutics deal

MITV said it will not extend a 2002 license agreement with ENDV to develop ENDV's PROstent Prostaglandin E-1 coating for use with MIVT's laser cut coronary stent delivery system to treat restenosis (see BioCentury, May...
08:00 , Mar 17, 2003 |  BC Week In Review  |  Company News

Angiogenix management update

Angiogenix Inc. , Burlingame, Calif.   Business: Cardiovascular   Hired: William Spickler as VP of pharmaceutical development, formerly senior medical director at Xoma Corp.  ...